발작성 야간혈색소뇨증 치료 세계 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 지역별, 부문별(2025-2030년)

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, Share & Trends Analysis Report By Treatment (Medication, Stem Cell Transplant, Blood Transfusion), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

발작성 야간혈색소뇨증 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 발작성 야간혈색소뇨증 치료 치료 세계 시장 규모는 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 9.6%를 기록하며, 2030년까지 99억 6,000만 달러에 달할 것으로 예측되고 있습니다.

혈액·골수 관련 질환 증가, 노인 인구 증가, 신규 치료제의 폭넓은 채용, 생물학적 제제의 출현 등, 여러 요인이 시장을 견인하고 있습니다.

발작성 야간혈색소뇨증 치료는 후천성 만성 혈액 질환입니다. 북미와 유럽에서 약 8,000-10,000례의 증례가 보고되고 있는 초희귀질환입니다. 생명을 위협하는 이 질환은 종종 혈전증, 지속성 혈관내 용혈, 범혈구 감소의 3가지 병태를 나타냅니다. 유병률에 대한 정보는 부족하지만 PNH는 세계 2만 명 이상이 병을 앓고 있는 것으로 추정되며 연간 발병률은 100만명당 약 1.3명, 유병률은 100만명당 약 16명입니다. PNH는 남녀에 관계없이 발병합니다. 신체 증상은 모든 연령대에서 발생할 수 있지만 일반적으로 30-40세 사이에 발생합니다.

단클론항체, 재조합 단백질, 환상 펩티드를 포함한 새로운 치료법이 신흥국 시장에서 침투하고 있습니다. 그러나 솔리리스 및 기타 신약 후보로 치료하는 것은 비용이 많이 들기 때문에 개발 도상 지역에서의 채용에는 장벽이 있습니다. 수혈과 지지 요법은 부작용과 효능이 최적이 아니기 때문에 예측 기간 동안 기세를 잃을 것으로 예상됩니다.

발작성 야간혈색소뇨증 치료 시장 : 분석 개요

• 미국에서는 추정 5,000-6,000명이 PNH를 앓고 있으며 연간 약 450건의 신규 사례가 보고되었습니다.
• 미국에서는 치료비가 높고, 다양한 파이프라인 의약품이 승인될 가능성이 있는 것, 신규 치료제가 채용되고 있기 때문에 2024년 세계 PNH 치료 시장은 미국이 큰 수익 점유율을 차지했습니다.
• 약수처리는 2024년 85.3% 이상의 점유율로 PNH 시장을 독점했습니다. 약물 이외에는 줄기세포 이식 분야가 예측 기간을 통해 2자리 성장을 이룰 것으로 예측됩니다.
• 현재 16개 제품이 PNH 치료제로 임상 평가 중이며 다양한 개발 단계에 있습니다. ALXN1210, Coversin, APL2, RA101495와 같은 유망한 파이프라인 후보는 약사 승인 후 상업적 가능성이 큽니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 발작성 야간혈색소뇨증 치료 시장 : 변동 요인·경향·범위

• 시장 연관 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 발작성 야간혈색소뇨증 치료 시장 : 치료법별 비즈니스 분석

• 시장 점유율 : 치료법별(2024년·2030년)
• 치료법별 대시보드
• 시장 규모 예측과 동향 분석 : 치료법별(2018-2030년)
• 투약
• 줄기세포 이식
• 수혈
• 기타 치료의 유형

제5장 발작성 야간혈색소뇨증 치료 시장 : 지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2030년)
• 시장 대시보드 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 국가별(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제6장 경쟁 구도

• 참가 기업 개요
• 기업 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일/상장 기업
  • Alexion Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Pfizer Inc.
  • Amgen Inc.

KTH

영문 목차

영문목차

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Growth & Trends:

The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to reach USD 9.96 billion by 2030, registering a CAGR of 9.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Several factors such as rise in the number of blood and bone marrow related disorders, an increase in the geriatric population, wider adoption of novel therapeutics, and the emergence of biologics are driving the market.

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, chronic hematologic disorder. It is an ultra-rare disease with approximately 8,000 to 10,000 cases reported in North America and Europe. The life-threatening disease often manifests in three forms: thrombosis, persistent intravascular hemolysis, and pancytopenia. Although the information on its prevalence is scarce, PNH is estimated to affect more than 20,000 people worldwide with an incidence of about 1.3 per million annually and a prevalence of around 16 per million. PNH affects men and women equally. Although physical symptoms can begin at any age, they usually develop between 30-40 years of age.

Novel treatments including monoclonal antibodies, recombinant proteins, and cyclic peptides are gaining penetration in developed markets. However, the high cost of therapy with Soliris and other emerging pipeline drugs presents a barrier in adoption in developing regions. Blood transfusion and supportive care are anticipated to lose momentum during the forecast period due to adverse side effects and suboptimal efficacy.

Paroxysmal Nocturnal Hemoglobinuria Treatment Market Report Highlights:

• An estimated 5,000 - 6,000 people in the U.S. suffer from PNH, with approximately 450 new cases being reported annually
• U.S. dominated the global PNH treatment market dominated with a significant revenue share in 2024 due to the high cost of treatment in the U.S., potential approval of a range of pipeline drugs, and adoption of novel therapeutics
• Treatment with medication dominated the PNH market with a share of more than 85.3% in 2024. Apart from drugs, the stem cell transplant segment is projected to witness double-digit growth through the forecast period
• Currently, 16 products are under clinical evaluation for PNH treatment in various stages of development. Promising pipeline candidates such as ALXN1210, Coversin, APL2, and RA101495 offer significant commercial potential post regulatory approval.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Billion)
• 4.4. Medication
  • 4.4.1. Medication Market, 2018 - 2030 (USD Billion)
• 4.5. Stem Cell Transplant
  • 4.5.1. Stem Cell Transplant Market, 2018 - 2030 (USD Billion)
• 4.6. Blood Transfusion
  • 4.6.1. Blood Transfusion Market, 2018 - 2030 (USD Billion)
• 4.7. Other Treatment Types
  • 4.7.1. Other Treatment Types Market, 2018 - 2030 (USD Billion)

Chapter 5. Paroxysmal Nocturnal Hemoglobinuria Treatment Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Regulatory Framework
    • 5.4.2.3. Competitive Insights
    • 5.4.2.4. U.S. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Regulatory Framework
    • 5.4.3.3. Competitive Insights
    • 5.4.3.4. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Regulatory Framework
    • 5.4.4.3. Competitive Insights
    • 5.4.4.4. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.5. Europe
  • 5.5.1. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Regulatory Framework
    • 5.5.2.3. Competitive Insights
    • 5.5.2.4. UK Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Regulatory Framework
    • 5.5.3.3. Competitive Insights
    • 5.5.3.4. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Regulatory Framework
    • 5.5.4.3. Competitive Insights
    • 5.5.4.4. France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Regulatory Framework
    • 5.5.5.3. Competitive Insights
    • 5.5.5.4. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Regulatory Framework
    • 5.5.6.3. Competitive Insights
    • 5.5.6.4. Spain Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.7. Norway
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Regulatory Framework
    • 5.5.7.3. Competitive Insights
    • 5.5.7.4. Norway Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.8. Denmark
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Regulatory Framework
    • 5.5.8.3. Competitive Insights
    • 5.5.8.4. Denmark Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5.9. Sweden
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Regulatory Framework
    • 5.5.9.3. Competitive Insights
    • 5.5.9.4. Sweden Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Regulatory Framework
    • 5.6.2.3. Competitive Insights
    • 5.6.2.4. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Regulatory Framework
    • 5.6.3.3. Competitive Insights
    • 5.6.3.4. China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Regulatory Framework
    • 5.6.4.3. Competitive Insights
    • 5.6.4.4. India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.5. South Korea
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Regulatory Framework
    • 5.6.5.3. Competitive Insights
    • 5.6.5.4. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.6. Australia
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Regulatory Framework
    • 5.6.6.3. Competitive Insights
    • 5.6.6.4. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Regulatory Framework
    • 5.6.7.3. Competitive Insights
    • 5.6.7.4. Thailand Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.7. Latin America
  • 5.7.1. Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Regulatory Framework
    • 5.7.2.3. Competitive Insights
    • 5.7.2.4. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Regulatory Framework
    • 5.7.3.3. Competitive Insights
    • 5.7.3.4. Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
• 5.8. MEA
  • 5.8.1. MEA Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Regulatory Framework
    • 5.8.2.3. Competitive Insights
    • 5.8.2.4. South Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Regulatory Framework
    • 5.8.3.3. Competitive Insights
    • 5.8.3.4. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Regulatory Framework
    • 5.8.4.3. Competitive Insights
    • 5.8.4.4. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Regulatory Framework
    • 5.8.5.3. Competitive Insights
    • 5.8.5.4. Kuwait Paroxysmal Nocturnal Hemoglobinuria Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Alexion Pharmaceuticals, Inc.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Treatment Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Apellis Pharmaceuticals
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Treatment Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Novartis AG
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Treatment Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. F. Hoffmann-La Roche Ltd
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Treatment Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Genentech, Inc.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Treatment Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. BioCryst Pharmaceuticals, Inc.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Treatment Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Regeneron Pharmaceuticals Inc.
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Treatment Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Sanofi
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Treatment Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Pfizer Inc.
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Treatment Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Amgen Inc.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Treatment Benchmarking
    • 6.5.10.4. Strategic Initiatives

관련자료